Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 833 results for "aml"

Study Highlights Importance of Achieving CR After Intensive Therapy for AML
Cancer Therapy Advisor

Phase 1b Study of Patients with Newly Diagnosed AML

Loading........ 23 views Description: Harry P. Erba, MD, PhD of the University of Alabama at Birmingham School of Medicine, presents a press brief on A Phase 1b Study of Vadastuximab Talirine in Combination with 7+3 Induction Therapy ... Oncology Tube, 1 hour ago

411 images for aml

PharmaVOICE, 1 day ago
The Times Of Israel, 1 day ago
CNN, 2 days ago
Med India, 1 day ago
BBC, 1 day ago
Before It's News, 19 hours ago
New Zealand Herald, 2 days ago
Woodstock Sentinel-Review, 2 days ago
Recorder and Times, 2 days ago
Business Insider India, 3 days ago

Daiichi Sankyo presents preliminary safety & efficacy data from phase 1 study of DS-3032 in AML &MDS at ASH meeting

Daiichi Sankyo Company, Limited announced preliminary safety and efficacy data from a phase 1 study of DS-3032, an investigational oral selective MDM2 inhibitor, suggesting that DS-3032 may be a promising treatment for haematological malignancies ...
 PharmaBiz18 hours ago BRIEF-Daiichi Sankyo presents Phase 1 Data for MDM2 Inhibitor DS-3032 in AML, MDS  Reuters UK2 days ago Daiichi Sankyo Presents Phase 1 Data for MDM2 Inhibitor DS-3032 in Acute Myeloid Leukemia and Myelodysplastic Syndrome at the 58th Annual Meeting of the American Society of Hematology  Bio-Medicine2 days ago U.S. FDA Grants Fast Track Designation for HER2-Targeting Antibody Drug Conjugate DS-8201 for HER2-Positive Metastatic Breast Cancer  Drugs.com13 hours ago
The Nation Pakistan

Stubbornness means doom: Sheikh Rashid

ISLAMABAD: Chief of Awami Muslim League (AML) Sheikh Rashid has said those requesting for constitution of commission in Panama leaks case should know it well that nothing would come out of commission. Those making request for constitution of ...
 The Nation Pakistan15 hours ago Rashid accuses PM of receiving $300 million in motorway kickbacks  The Express Tribune19 hours ago Nawaz Sharif's doom is nearing close: Sheikh Rashid  Online News Pakistan1 day ago People believe flats belong to Sharif family: Sheikh Rashid  SAMAA TV1 day ago

Alternative Option to Intensive Chemotherapy for Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Yale Cancer Center team has evaluated the use of hypomethylating agents in patients suffering from Acute Myeloid Leukemia (AML) who were resistant to treatment with
 Infrosoft1 day ago Decitabine an option for select AML, MDS patients  MedWire News2 days ago

New phase 2 results show glasdegib improved overall survival in AML & high-risk MDS

Pfizer Inc. announced new data from a randomized phase 2 study of glasdegib (PF-04449913), an oral, smoothened (SMO) inhibitor, showing the addition of glasdegib to low-dose cytarabine (LDAC) significantly increased overall survival (OS) when ...
 PharmaBiz2 days ago Pfizer's Glasdegib improves OS in AML and MDS patients in phase 2 trial  Pharmaceutical Business Review2 days ago Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome  Drugs.com13 hours ago Pfizer (PFE) Presents Favorable Data on Leukemia Candidate  Yahoo! Canada2 days ago

BioLineRx Presents Positive Phase 2a AML Study and Mechanism-of-Action Data for BL-8040 Oncology Platform at ASH..

/PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, presents positive Phase 2a correlative data, as well as ...
 ADVFN India2 days ago BRIEF-BioLine RX presents positive phase 2a AML study and mechanism-of-action data for BL-8040 oncology platform at ASH 2016  Reuters UK2 days ago BioLineRx lead product candidate beats cytarabine in myeloid leukemia study  Seeking Alpha2 days ago
International Business Times India

USFDA designates Novartis' AML treatment as breakthrough therapy

 International Business Times India3 days ago

India has zero conviction on money laundering: US reports

The PMLA was introduced in 2002 and was amended in 2012 to align with international laws related to AML/CFT
 DNA1 week ago

Karyopharm Presents Updated Phase II SAIL Relapsed/Refractory AML Clinical Data At The American Society of Hematology 2016 Annual Meeting

- Data Demonstrate Robust Response Rates Enabling Transplantation or Donor Lymphocyte Infusions in Patients with Heavily Pretreated Acute Myeloid Leukemia - NEWTON, Mass., Dec. 04, 2016 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc.
 BioSpace2 days ago Karyopharm Presents Updated Phase 2 SAIL Relapsed/Refractory AML Clinical Data at the American Society of Hematology 2016 Annual Meeting  SPi World News3 days ago Verastem Presents Phase 2 DYNAMO Clinical Data At American Society of Hematology 2016 Annual Meeting  BioSpace1 day ago Karyopharm Presents Updated Phase 1b STOMP Data at the American Society of Hematology 2016 Annual Meeting  Minyanville1 day ago

Cornerstone Pharmaceuticals, Inc. Presents Phase I Data on CPI-613 in Acute Myeloid Leukemia (AML) and T-Cell..

CRANBURY, N.J. CPI-613 is Cornerstone Pharmaceuticals' lead Altered Energy Metabolism Directed (AEMD) drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting ...
 ADVFN UK1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less